Production and Purification of Polyclonal Antibodies against Diphtheria Toxin

Document Type : Original Article


1 Biology Research Center, Faculty and Institute of Basic Science, Imam Hossein University, Tehran, Iran

2 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran


Diphtheria is a fatal disease caused by exotoxin of Corynebacterium diphtheria.  This toxin consists of two chains, catalytic chain (A) and binding (B) chain. By binding chain (B), the toxin binds to its receptor on numerous body cells such as myocardial, kidney and peripheral nerve cells. After entering, catalytic chain (A) inhibits protein synthesis and finally can cause cell death. At this time, the toxoid form of diphtheria toxin is used as vaccine. The aim of this study was the immunological analysis of the mutated synthetic catalytic subunit of diphtheria toxin in laboratory animals as a vaccine candidate, in addition to polyclonal antibody production and purification against diphtheria toxin. For this purpose the Dtx recombinant protein (with two mutant: A158G and G52E) was expressed using pET28a/DtxA plasmid in E. coli Bl21DE3 host. Then, recombinant protein, as a candidate vaccine, was extracted and purified. After evaluating and confirming the protein by SDS-PAGE and western blotting, immunization carried out in laboratory animals. Finally, followed by antibody titration by ELISA, antibody purification performed as well.The mutated recombinant protein prepared from an optimized expression was extracted and purified. Then, this protein was confirmed by SDS-PAGE and western blotting. ELISA results showed a satisfactory immunization of animals by this protein. Polyclonal antibody production and purification against diphtheria toxin was performed by G protein column and confirmed by ELISA. ELISA results showed a high titer of polyclonal antibody against diphtheria toxin in animal's serum after immunization by recombinant DTx protein.


  1. WHO: WHO’s contributions to world health, p. 49-76. In The world health report, World Health Organization, Geneva (1995).
  2. WHO: The state of world health, p. l-62. In The world health report, World Health Organization, Geneva (1996)
  3. Milstein, J. B., Gellin, B.G., Kane, M., Fabio, J.L., and Homma, A., Global DTP manufacturing capacity and capability, Status report. Vaccine 1995, Vol. 14, pp. 313-320.
  4. Mueller, J.H., A simplified formula for diphtheria toxin broth. J Immun, 1939, Vol. 37, pp. 103-112.
  5. Edwards, D.C., The growth and toxin production of Corynebacterium diphtheriae in submerged culture. J Gen Microbiol, 1960, Vol. 22, pp. 698-704.
  6. Righelato, R., and Van Hemert, P.A., Growth and toxin synthesis in batch and chemostat cultures of Corynebacterium diphtheria. J  Gen Microbiol, 1969, Vol. 58, pp. 403-410.
  7. Pope, C.G., and Muriel, F., Purification of diphtheria toxoid. J Bacteriol Virolo, 1975, Vol. 139, pp. 61-64.
  8. WHO: Manual for the production and control of vaccines. Diphtheria toxoid. 1977; BLG/UNDP/77-I Rev.
  9. Kasauli, H.P., Manual for the production and standardization of Diphtheria-Pertussis-Tetanus Vaccine, Central Research Institute, India C.R.I, 1989.
  10. Collier, et al. Recombinant diphtheria toxin A fragment muteins .US Patent 4709017, 1987.
  11. Sundaran, B., Rao, Y.U., and Boopathy, R., Process optimization for enhanced production of diphtheria toxin by submerged cultivation. J Biosci Bioeng, 2001, Vol. 91, pp. 123-128.
  12. WHO: Expert-committee on biological standardization. Requirements for diphtheria and tetanus toxoid. WHO Tech Rep Ser, No. 293, 1964.
  13. Seamer, P.A., Estimation of microgram quantities of iron in culture medium, using bathophenanthroline. Nature, 1959, Vol. 184, pp. 636-637.
  14. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, Vol. 227, pp. 680-685.
  15. Niclas R., Development of New Oral Vaccine against Diphtheria and the Study of its Immunogenicity in Mouse and Man. PhD Thesis, ACTA Universities 2004.
  16. Major Brown, H.C., Further observations on the standardization of bacterial suspensions. Ind J Med Res, 1919, Vol. 7, pp. 238-250.
  17. Ramon, G., Flocculation test for assaying toxin, toxoid and antitoxin. Compt Rend Soc Biol, 1922, Vol. 86, pp. 711-712.
  18. Tasman, A., and Braod wijk, AC., Experiments on metabolism with diphtheria. J Infect Dis, 1938, Vol. 63, pp. 10-20.
  19. Pappenheimer, A.M., and Johnson, S.J., Studies in diphtheria production. I. The effect of iron and coppe. Br J Exp Path, 1936, Vol. 17, pp. 335-341.
  20. Mueller, J.H. and Pauline, A.M., Production of diphtheria toxin of high potency (1OOLf) oh a reproducible medium. J  Immunol, 1941, Vol. 48, pp. 321-322.
  21. Stainer, D.W., Separation of bovine sensitizing material from papain digest of beef broth. Can J Microbiology, 1967, Vol. 13, pp. 1001-1008.
  22. Moghadam, A.T., and Afsharpad, K., Application of fermentor technology in production of diphtheria toxin. Jundishapur J Microbiol, 2008, Vol. 1, pp. 24-27.
  23. Tchorbanov, A. I., Dimitrov, J.D., and Vassilev, T.L., Optimization of casein-based semisynthetic medium for growing of toxigenic Corinebacterium diphtheriae in a fermenter. Can J Microbiol, 2004, Vol. 50, pp. 821-826.
  24. Lobeck, K., Drevet, P., Leonetti, M., Fromen-Romano, C., Ducancel, F., Lajeunesse, E., et al., Towards a recombinant vaccine against diphtheria toxin. Infect Immun, 1998, Vol. 66, pp. 418-423.
  25. Miyaji, E. N., Mazzantini, R.P., Dias, W.O., Nascimento, A.L., Marcovistz, R., Matos, D.S., et al., Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun, 2001, Vol. 69, pp. 869-874.
  26. McNeela, E.A., David, O.A., Inderjit, J.G.B., Lisbeth, I. B., Stanley, S., Davis, B., et al., A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine Res, 2001, Vol. 19, pp. 1188-1198.
  27. Pappenheimer, A., Diphtheria toxin. Annu Rev Biochem, 1977, Vol. 46, pp. 69 - 94.
  28. WHO. Manual for the production and control of vaccine, diphtheria toxoid. 1990; (BLG/ UNDP /77.3 rev1.
  29. WHO.  Expert committee on biological standardization. 1981; 659: 16-19.
  30. Francis, J.W., Brown, R.H., Figueiredo, D., Remington, M.P., Castillo, O., Schwarzschild, M. A., et al., Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J Neurochem, 2000, Vol. 74, pp. 2528-2536.
  31. Rodnin, M.V., Alexander, K., Paul, K., Onkar, S., Yevgen, O., Posokhov, R., John, C., Alan, F. and Alexey, S., Conformational Switching of the Diphtheria Toxin T Domain. J Mol Bio, 2010, Vol. 402, pp. 1-7.
  32. Efstratiou, A. and Roure, C., The European Laboratory Working Group on Diphtheria: A global microbiologic network. J Infect Dis, 2000, Vol. 181 (1), pp. S146-51.